<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062254</url>
  </required_header>
  <id_info>
    <org_study_id>17-029</org_study_id>
    <nct_id>NCT03062254</nct_id>
  </id_info>
  <brief_title>Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy</brief_title>
  <official_title>Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Broadly, the objective of this study is to evaluate the fractional decline of intensity of&#xD;
      tracer uptake measured by SUVmax on 68Ga-PSMA PET/CT in bone metastases from prostate cancer&#xD;
      following treatment with radium-223 as a surrogate marker for tumor cell killing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 22, 2018</start_date>
  <completion_date type="Actual">July 15, 2021</completion_date>
  <primary_completion_date type="Actual">July 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUV-max</measure>
    <time_frame>6 months</time_frame>
    <description>fractional decline of intensity of tracer uptake measured by SUVmax on 68Ga-PSMA PET/CT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radium-223</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>radium-223 dichloride</intervention_name>
    <description>6 doses of Radium-223</description>
    <arm_group_label>Radium-223</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Resident of Canada&#xD;
&#xD;
          -  Male sex&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Progressive (symptoms, conventional imaging, PSA, bone scan, FCH PET/CT or other)&#xD;
             castration-resistant prostate cancer in the judgment of the treating physician without&#xD;
             change in systemic anti-neoplastic therapy since documented progression&#xD;
&#xD;
          -  Six or greater bone metastases robustly-avid on recent (4 weeks) MDP or NaF&#xD;
             scintigraphy&#xD;
&#xD;
          -  Recently failed (within 3 months) or failing novel androgen receptor pathway&#xD;
             inhibitors (abiraterone + prednisone or enzalutamide) with intention of continuing the&#xD;
             drug for at least 7 months OR minimum 14 day washout period from either agent prior to&#xD;
             study enrollment&#xD;
&#xD;
          -  No known visceral metastases or adenopathy greater than 3 cm short axis on&#xD;
             conventional imaging&#xD;
&#xD;
          -  Not received docetaxel for castration-resistant disease&#xD;
&#xD;
          -  ECOG performance status 0 - 2, inclusive&#xD;
&#xD;
          -  Life expectancy of greater than 6 months&#xD;
&#xD;
          -  Serum testosterone less than or equal to 50 ng/dl&#xD;
&#xD;
          -  Hemoglobin greater than or equal to 100 g/L with no blood transfusions or EPO in&#xD;
             preceding 3 weeks&#xD;
&#xD;
          -  Neutrophils greater than or equal to 1.5 x109/L&#xD;
&#xD;
          -  Platelets greater than or equal to 100 x109/L&#xD;
&#xD;
          -  No prior hemi-body radiotherapy&#xD;
&#xD;
          -  No impending or established spinal cord compression&#xD;
&#xD;
          -  No unmanageable fecal incontinence&#xD;
&#xD;
          -  Patient has good IV access&#xD;
&#xD;
          -  Able to understand and provide written informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Planned change in systemic anti-neoplastic therapy during the approximately 7 month&#xD;
             trial&#xD;
&#xD;
          -  Unable to tolerate the physical/logistical requirements of a PET/CT scan including&#xD;
             lying supine for up to 30 minutes with the arms above the head and tolerating&#xD;
             intravenous cannulation for injection of the study drug.&#xD;
&#xD;
          -  Medically unstable patients (e.g. acute cardiac or respiratory distress or&#xD;
             hypotensive, etc.)&#xD;
&#xD;
          -  Patients who exceed the safe weight limit of the PET/CT bed (approximately 400 lbs.)&#xD;
             or who cannot fit through the PET/CT bore (70 cm diameter)&#xD;
&#xD;
          -  Patients who are claustrophobic&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>male only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Stephan Probst, MD</investigator_full_name>
    <investigator_title>Chief of Nuclear Medicine</investigator_title>
  </responsible_party>
  <keyword>PSMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

